Combination cancer immunotherapies tailored to the tumour microenvironment (Q38645178)

5 September 2017

title

Combination cancer immunotherapies tailored to the tumour microenvironment (English)

1 reference

5 September 2017

1 reference

1

1 reference

5 September 2017

3

Antoni Ribas

1 reference

5 September 2017

Shin Foong Ngiow

2

1 reference

5 September 2017

Michele W L Teng

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

24 November 2015

1 reference

Nature Reviews Clinical Oncology

5 September 2017

published in

1 reference

5 September 2017

volume

13

1 reference

5 September 2017

issue

3

1 reference

5 September 2017

page(s)

143-158

1 reference

The future of immune checkpoint therapy

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

From mice to humans: developments in cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Classifying Cancers Based on T-cell Infiltration and PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Anti-CTLA4 Antibody Clinical Trials in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

21 January 2018

Bispecific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The coming of age of engineered multivalent antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Ipilimumab and its toxicities: a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Combination cancer immunotherapy and new immunomodulatory targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Targeting cancer-derived adenosine: new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Macrophages and cancer: from mechanisms to therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Macrophage regulation of tumor responses to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

A balance of interleukin-12 and -23 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Bevacizumab: overview of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The immune contexture of primary and metastatic human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The Yin and Yang of Toll-like receptors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

IL-2: the first effective immunotherapy for human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Type I interferons in anticancer immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Combined natural killer T-cell based immunotherapy eradicates established tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

TLR agonists: our best frenemy in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

c-kit(+) cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Opportunities and challenges of radiotherapy for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Combining radiotherapy and cancer immunotherapy: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Radiation and immunotherapy: a synergistic combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Radiotherapy complements immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Update on the role of ipilimumab in melanoma and first data on new combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Combining cancer immunotherapy and targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Restoration of p53 function leads to tumour regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Surgery induced immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Sipuleucel-T for the treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Gene-engineered T cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Why does cytotoxic chemotherapy cure only some cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Host b7x promotes pulmonary metastasis of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Structure and cancer immunotherapy of the B7 family member B7x

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD73-deficient mice are resistant to carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Immunological mechanisms of the antitumor effects of supplemental oxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Significance of M2-polarized tumor-associated macrophage in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

CD47 blockade triggers T cell-mediated destruction of immunogenic tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

B7-H5 costimulates human T cells via CD28H

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

TIGIT predominantly regulates the immune response via regulatory T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.209

Radiation as an immunological adjuvant: current evidence on dose and fractionation.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26598942

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Role of T lymphocytes in tumor response to radiotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26598942

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Blocking IDO activity to enhance anti-tumor immunity.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26598942

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2015.209

1 reference

5 September 2017

1 reference